New Treatment for CLL in USA

Patients living in the USA who have chronic lymphocytic leukaemia (CLL) now have a new treatment option with the approval of ibrutinib (Imbruvica). The Food and Drug Administration approved the use of ibrutinib in patients

with CLL who have received at least one previous therapy. Results from a phase Ib/II trial in which 48 patients with relapsed or refractory CLL received ibrutinib showed that 58% of them achieved an overall response rate that ranged from 5.6 months to 24.2 months. Ibrutinib was approved in November 2013 for the treatment of mantle cell lymphoma in patients who had received at least one prior treatment. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.